Fight against hopelessness Curocell, a leader of development of innovative immune cell therapy, reaches out a hand to numbers of cancer patients in despair Curocell, a leader of developing innovative anti-cancer immune cell therapy, reaches out a hand to numbers of cancer patients in despair
About

We are developing innovative immune
cell therapy
using cutting-edge gene
engineering technology.

About

We are developing innovative immune
cell therapy
using cutting-edge gene
engineering technology.

We are developing innovative immune cell therapy using cutting-edge gene engineering technology.

NEWS

Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy

  – CRC01 downregulates PD1 and TIGIT to overcome the immune suppression in the tumor microenvironment – Up to 100…

기적의 항암제 세계 첫 임상? 고형암 치료 ‘CAR-T치료제’

김건수 큐로셀 대표 인터뷰 이달 식약처 임상허가 기대 면역세포 유전자 조작후 배양 환자 재투여 첨단세포치료제 급성백혈병·림프종 완치가능 유전자 조작해 고형암도 효과…

NEWS

기적의 항암제 세계 첫 임상? 고형암 치료 ‘CAR-T치료제’

김건수 큐로셀 대표 인터뷰 이달 식약처 임상허가 기대 면역세포 유전자 조작후 배양 환자 재투여 첨단세포치료제 급성백혈병·림프종 완치가능 유전자 조작해 고형암도 효과…

큐로셀, 시리즈C 440억원 투자유치… CAR-T 개발 가속화

바이오 전문 투자기관 대거 참여 CAR-T 치료제 개발 전문기업 큐로셀은 440억원 규모의 ‘시리즈C’ 투자 유치에 성공했다고 10일 밝혔다. 2017년 창업…

R&D

Our technology is evolving
beyond the limitations
of current immune cell therapies.

We expect
improved anti-cancer effects
by applying our innovative technology.

Curocell produce
the innovative immune cell product in
GMP facility that complies with current regulation.

R&D

Our technology is evolving
beyond the limitations of
current immune cell therapies.

Our technology is evolving beyond the limitations of current immune cell therapies.

We expect improved
anti-cancer effects by
applying our innovative technology.

We expect improved anti-cancer effects by applying our innovative technology.

Curocell produce the innovative
immune cell product in GMP facility
that complies with current regulation.

Curocell produce the innovative immune cell product in GMP facility that complies with current regulation.